---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-000526"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2025-01-30T23:59:59+00:00"
generated_at: "2026-05-27T05:10:15.343173+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MaxCyte acquires SeQure Dx for $4.5M cash; adds gene-editing safety assessment services

## Summary
- Initial consideration $4.5M in cash; up to $2.5M additional contingent on revenue targets.
- SeQure reported ~$1.7M revenue and ~$6.5M loss (Jan–Nov 2024 unaudited); net assets $0.7M.
- Acquisition expected to be accretive to MaxCyte's revenue growth; expands cell/gene therapy offerings.
- SeQure specializes in on-target and off-target editing assessments for viral and non-viral modalities.

## SEC filing metadata
- accession: 0001558370-25-000526
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2025-01-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000155837025000526/0001558370-25-000526-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000155837025000526/mxct-20250130x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-000526
- JSON: https://secwatch.observer/filing/0001558370-25-000526.json
- Plain text: https://secwatch.observer/filing/0001558370-25-000526.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.